Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) that has shown efficacy in B-cell non-Hodgkin’s lymphoma. It has shown high efficacy in relapsed/refractory follicular lymphoma (FL) even in the presence of high risk features (early relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohty, Razan, Kharfan-Dabaja, Mohamed A, Chavez, Julio C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122857/
https://www.ncbi.nlm.nih.gov/pubmed/37155519
http://dx.doi.org/10.2147/CMAR.S368588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122857/
https://www.ncbi.nlm.nih.gov/pubmed/37155519
http://dx.doi.org/10.2147/CMAR.S368588

Ejemplares similares